Sangamo Therapeutics General and Administrative Expenses 2011-2026 | SGMO

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Sangamo Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
34.9 M	44.7 M	61.2 M	62.7 M	63.2 M	67.1 M	61.7 M	46.7 M	27.2 M	26.3 M	19.2 M	15.7 M	13.8 M	12.1 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
67.1 M	12.1 M	39.8 M

Quarterly General and Administrative Expenses Sangamo Therapeutics

2025-Q3	2025-Q2	2024-Q3	2024-Q2	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.99 M	9.08 M	11 M	12 M	13.9 M	16 M	18.1 M	-	16.2 M	15.1 M	14.9 M	-	14.5 M	16.5 M	16.1 M	-	16.2 M	17.9 M	16.1 M	-	14.9 M	14.6 M	17.1 M	-	11 M	11.3 M	10.1 M	-	6.42 M	6.04 M	7.28 M	-	5.02 M	11.1 M	5.36 M	-	4.56 M	5.02 M	4.73 M	-	3.73 M	3.97 M	3.64 M	-	3.16 M	3.12 M	3.31 M	-	3.14 M	2.74 M	3.24 M	-	3.59 M	3.68 M	3.54 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.1 M	2.74 M	9.47 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Autolus Therapeutics plc AUTL	132 M	$ 1.36	-2.52 %	$ 362 M	Britain
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
DBV Technologies S.A. DBVT	32.8 M	$ 20.25	-0.54 %	$ 2.83 B	France
Dyadic International DYAI	890 K	$ 0.87	0.59 %	$ 31.5 M	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.78	4.83 %	$ 9.09 B	Australia
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	17.4 M	$ 2.6	-2.26 %	$ 16.3 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Fate Therapeutics FATE	46.5 M	$ 1.14	-4.2 %	$ 135 M	USA
Forte Biosciences FBRX	12.4 M	$ 26.44	-	$ 342 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Fennec Pharmaceuticals FENC	28.3 M	$ 6.16	-4.05 %	$ 176 M	USA
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Amicus Therapeutics FOLD	383 M	$ 14.46	0.03 %	$ 4.46 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Fulcrum Therapeutics FULC	28.7 M	$ 7.57	-3.32 %	$ 480 K	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Galectin Therapeutics GALT	5.8 M	$ 2.28	-11.13 %	$ 146 M	USA
Gilead Sciences GILD	5.77 B	$ 138.34	-1.28 %	$ 172 B	USA
Galmed Pharmaceuticals Ltd. GLMD	5.66 M	$ 0.54	4.28 %	$ 503 K	Israel
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Genmab A/S GMAB	661 M	$ 27.14	-2.2 %	$ 17 B	Danmark
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
BioNTech SE BNTX	286 M	$ 88.2	-3.37 %	$ 27.2 B	Germany
Gossamer Bio GOSS	37.6 M	$ 0.32	-7.11 %	$ 73.1 M	USA
Coherus BioSciences CHRS	101 M	$ 1.62	-3.29 %	$ 190 M	USA
Grifols, S.A. GRFS	1.06 B	$ 7.98	-3.04 %	$ 6.83 B	Spain
Akari Therapeutics, Plc AKTX	9.28 M	$ 3.5	-1.13 %	$ 236 B	Britain
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
GT Biopharma GTBP	8.95 M	$ 0.41	-8.56 %	$ 2.26 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	1.21 B	$ 316.69	-4.13 %	$ 41.5 B	USA
Halozyme Therapeutics HALO	207 M	$ 63.72	1.01 %	$ 7.64 B	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	10.9 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Harmony Biosciences Holdings HRMY	153 M	$ 27.53	-0.67 %	$ 1.58 B	USA
Burford Capital Limited BUR	99.3 M	$ 4.53	1.0 %	$ 726 M	Britain
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA